NASDAQ:MMSI', 'Merit Medical Systems Inc.', 'http://kldaily.com/kl-logo.png');

Key Analysts at Canaccord Genuity Kept their ‘”Buy”’ rating for Merit Medical Systems (NASDAQ:MMSI) Shares Today. Their Price Target is Set to $45.0

December 10, 2017 - By Marie Mckinney

 Key Analysts at Canaccord Genuity Kept their ‘

Investors sentiment is 1.49 in 2017 Q2. Its the same as in 2017Q1. It is without change, as 19 investors sold Merit Medical Systems, Inc. shares while 52 reduced holdings. only 38 funds opened positions while 68 raised stakes. 44.02 million shares or 2.45% more from 42.97 million shares in 2017Q1 were reported.

1492 Capital Mngmt Limited Liability Corp reported 27,880 shares stake. Massachusetts Ser Com Ma accumulated 494,960 shares. Raymond James & Associate, Florida-based fund reported 44,195 shares. Rhumbline Advisers holds 0.01% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 92,785 shares. Credit Suisse Ag has invested 0% in Merit Medical Systems, Inc. (NASDAQ:MMSI). State Board Of Administration Of Florida Retirement reported 0% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI). Citigroup has invested 0% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI). 3,650 are held by Panagora Asset Mngmt. Kennedy Capital Management holds 0.15% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 208,847 shares. Eagle Asset Mgmt reported 0.14% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI). Raymond James Financial Service has invested 0% in Merit Medical Systems, Inc. (NASDAQ:MMSI). Moreover, Metropolitan Life Insurance Co New York has 0.01% invested in Merit Medical Systems, Inc. (NASDAQ:MMSI). Bancorporation Of New York Mellon Corporation holds 0.01% or 613,730 shares. 384,901 were accumulated by Partner Fund Management Ltd Partnership. Voya Investment Limited Liability has 0.07% invested in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 860,097 shares.

Merit Medical Systems (NASDAQ:MMSI) Rating Reaffirmed

Canaccord Genuity now has a $45.0 TP on shares of Merit Medical Systems (NASDAQ:MMSI). The TP gives a potential upside of 3.93 % from the close price of Merit Medical Systems (NASDAQ:MMSI). This rating was revealed to investors in a research report on 8 October.

Investors sentiment is 1.49 in 2017 Q2. Its the same as in 2017Q1. It is without change, as 19 investors sold Merit Medical Systems, Inc. shares while 52 reduced holdings. only 38 funds opened positions while 68 raised stakes. 44.02 million shares or 2.45% more from 42.97 million shares in 2017Q1 were reported.

1492 Capital Mngmt Limited Liability Corp reported 27,880 shares stake. Massachusetts Ser Com Ma accumulated 494,960 shares. Raymond James & Associate, Florida-based fund reported 44,195 shares. Rhumbline Advisers holds 0.01% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 92,785 shares. Credit Suisse Ag has invested 0% in Merit Medical Systems, Inc. (NASDAQ:MMSI). State Board Of Administration Of Florida Retirement reported 0% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI). Citigroup has invested 0% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI). 3,650 are held by Panagora Asset Mngmt. Kennedy Capital Management holds 0.15% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 208,847 shares. Eagle Asset Mgmt reported 0.14% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI). Raymond James Financial Service has invested 0% in Merit Medical Systems, Inc. (NASDAQ:MMSI). Moreover, Metropolitan Life Insurance Co New York has 0.01% invested in Merit Medical Systems, Inc. (NASDAQ:MMSI). Bancorporation Of New York Mellon Corporation holds 0.01% or 613,730 shares. 384,901 were accumulated by Partner Fund Management Ltd Partnership. Voya Investment Limited Liability has 0.07% invested in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 860,097 shares.

Merit Medical Systems, Inc. (NASDAQ:MMSI) Ratings Coverage

Among 8 analysts covering Merit Medical (NASDAQ:MMSI), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Merit Medical has $51.0 highest and $22 lowest target. $43.58’s average target is 0.65% above currents $43.3 stock price. Merit Medical had 17 analyst reports since October 23, 2015 according to SRatingsIntel. Barrington Research downgraded Merit Medical Systems, Inc. (NASDAQ:MMSI) on Friday, October 23 to “Mkt Perform” rating. The firm has “Buy” rating given on Monday, July 10 by Canaccord Genuity. The firm has “Buy” rating given on Sunday, October 8 by Canaccord Genuity. On Thursday, October 26 the stock rating was maintained by Canaccord Genuity with “Buy”. SunTrust maintained it with “Buy” rating and $47.0 target in Thursday, November 16 report. The stock has “Buy” rating by Bank of America on Thursday, July 20. The stock has “Buy” rating by Wells Fargo on Thursday, November 30. Craig Hallum maintained Merit Medical Systems, Inc. (NASDAQ:MMSI) rating on Thursday, July 27. Craig Hallum has “Buy” rating and $5000 target. The firm earned “Buy” rating on Thursday, November 16 by Canaccord Genuity. On Monday, September 4 the stock rating was maintained by Canaccord Genuity with “Buy”.

The stock decreased 1.25% or $0.55 during the last trading session, reaching $43.3. About 257,918 shares traded. Merit Medical Systems, Inc. (NASDAQ:MMSI) has risen 81.84% since December 10, 2016 and is uptrending. It has outperformed by 65.14% the S&P500.

Analysts await Merit Medical Systems, Inc. (NASDAQ:MMSI) to report earnings on February, 20. They expect $0.32 earnings per share, up 3.23 % or $0.01 from last year’s $0.31 per share. MMSI’s profit will be $16.07M for 33.83 P/E if the $0.32 EPS becomes a reality. After $0.32 actual earnings per share reported by Merit Medical Systems, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Merit Medical Systems, Inc. designs, develops, makes, and markets medical products for interventional and diagnostic procedures worldwide. The company has market cap of $2.17 billion. The companyÂ’s Cardiovascular segment offers cardiology and radiology devices for diagnosing and treating coronary arterial, peripheral vascular, and other non-vascular diseases; and embolotherapeutic products. It has a 73.76 P/E ratio. It also provides vascular access products; guide wires, inflation devices, and diagnostic catheters for use in angiography procedures; therapeutic infusion systems and safety products; drainage catheters and drainage access products, support catheters, vascular retrieval devices, and dialysis access products; and embosphere microspheres and delivery systems, and microcatheters.

More notable recent Merit Medical Systems, Inc. (NASDAQ:MMSI) news were published by: Seekingalpha.com which released: “Merit Medical – Becton And Bard Deal Looks Nice” on November 17, 2017, also Globenewswire.com with their article: “Merit Medical Announces Appointment of New Director” published on May 26, 2017, Globenewswire.com published: “Merit Medical to Participate at Five Conferences” on August 29, 2017. More interesting news about Merit Medical Systems, Inc. (NASDAQ:MMSI) were released by: Globenewswire.com and their article: “Merit Medical Systems to Announce Second Quarter Results on July 26, 2017” published on July 10, 2017 as well as Seekingalpha.com‘s news article titled: “Merit Medical Systems: Buy On The Dip” with publication date: November 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.